Publications
Detailed Information
Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: A randomized controlled split-face trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huh, Sun Young | - |
dc.contributor.author | Shin, Jung-Won | - |
dc.contributor.author | Na, Jung-Im | - |
dc.contributor.author | Huh, Chang-Hun | - |
dc.contributor.author | Park, Kyoung-Chan | - |
dc.contributor.author | Youn, Sang-Woong | - |
dc.date.accessioned | 2012-07-04T02:06:25Z | - |
dc.date.available | 2012-07-04T02:06:25Z | - |
dc.date.issued | 2010-04 | - |
dc.identifier.citation | JOURNAL OF DERMATOLOGY; Vol.37(4); 311-315 | ko_KR |
dc.identifier.issn | 0385-2407 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78375 | - |
dc.description.abstract | Melasma is an acquired pigmentary disorder that most commonly occurs in women of child-bearing age. Melasma is therapeutically challenging, and most commercially available hypopigmenting agents include tyrosinase inhibitors, which regulate the rate-limiting step of melanogenesis. 4-n-Butylresorcinol has received considerable attention as a novel hypopigmenting agent in the last 15 years because it has an inhibitory effect against tyrosinase and tyrosinase-related protein-1. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies. Liposome encapsulation is known to improve stabilization and enhance penetration of the product. Therefore, this study was conducted to evaluate the hypopigmenting efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream in patients with melasma. This was a randomized, double-blind, vehicle-controlled and split-face comparison study. Twenty-three patients with a clinical diagnosis of melasma were included. 4-n-Butylresorcinol 0.1% cream or vehicle was applied to each side of the face twice daily for 8 weeks. Clinical and photographic evaluations, Mexameter measurements and assessment of patient satisfaction and side-effects were performed at baseline, 4 and 8 weeks. All subjects completed the study. Mexameter measurements demonstrated that the melanin index of the 4-n-butylresorcinol-treated side showed a significant decrease when compared with the vehicle-treated side after 8 weeks (P = 0.043). No adverse reactions were observed throughout the study. Subjectively, 4-n-butylresorcinol was considered to be efficacious in more than 60% of the patients after 8 weeks of treatment. In conclusion, liposome-encapsulated 4-n-butylresorcinol 0.1% cream was well tolerated and showed significant higher efficacy than vehicle alone for the treatment of melasma. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | liposome-encapsulated 4-n-butylresorcinol | ko_KR |
dc.subject | treatment | ko_KR |
dc.subject | split-face design | ko_KR |
dc.subject | melasma | ko_KR |
dc.subject | randomized controlled trial | ko_KR |
dc.title | Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: A randomized controlled split-face trial | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 허선영 | - |
dc.contributor.AlternativeAuthor | 신정원 | - |
dc.contributor.AlternativeAuthor | 나정임 | - |
dc.contributor.AlternativeAuthor | 허창훈 | - |
dc.contributor.AlternativeAuthor | 윤상웅 | - |
dc.contributor.AlternativeAuthor | 박경찬 | - |
dc.identifier.doi | 10.1111/j.1346-8138.2010.00787.x | - |
dc.citation.journaltitle | JOURNAL OF DERMATOLOGY | - |
dc.description.citedreference | de Leeuw J, 2009, J EUR ACAD DERMATOL, V23, P505, DOI 10.1111/j.1468-3083.2009.03100.x | - |
dc.description.citedreference | Kanehara S, 2007, J DERMATOL, V34, P811, DOI 10.1111/j.1346-8138.2007.00391.x | - |
dc.description.citedreference | Khemis A, 2007, BRIT J DERMATOL, V156, P997, DOI 10.1111/j.1365-2133.2007.07814.x | - |
dc.description.citedreference | Date AA, 2006, SKIN PHARMACOL PHYS, V19, P2, DOI 10.1159/000089138 | - |
dc.description.citedreference | Kim DS, 2005, BIOL PHARM BULL, V28, P2216 | - |
dc.description.citedreference | AKASAKA T, 2002, ENV DERM, V9, P11 | - |
dc.description.citedreference | Shimizu K, 2000, PLANTA MED, V66, P11, DOI 10.1055/s-2000-11113 | - |
dc.description.citedreference | Cassano N, 1999, J EUR ACAD DERMATOL, V13, P14 | - |
dc.description.citedreference | *RES COMM RUC, 1999, NISHINIHON J DERMATO, V61, P813 | - |
dc.description.citedreference | Tasaka K, 1998, METHOD FIND EXP CLIN, V20, P99 | - |
dc.description.citedreference | KATAGIRI T, 1998, 20 IFSCC INT C, V39, P1 | - |
dc.description.citedreference | Dreher F, 1996, SKIN PHARMACOL, V9, P124 | - |
dc.description.citedreference | OKUBO T, 1995, J DERMATOL SCI, V10, P88 | - |
dc.description.citedreference | KOBAYASHI T, 1994, EMBO J, V13, P5818 | - |
dc.description.citedreference | SCHMID MH, 1994, CRIT REV THER DRUG, V11, P97 | - |
dc.description.citedreference | HEARING VJ, 1991, FASEB J, V5, P2902 | - |
dc.description.citedreference | ARTMANN C, 1990, PARFUM KOSM, V90, P326 | - |
dc.description.citedreference | ANSTEY A, 1990, J DERMATOL TREAT, V1, P199 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.